Industry Insights

  1. Driving Efficiencies: The Power Of Platform Processes And Digital Access 9/23/2024

    Unlocking the potential of next-generation therapeutics requires extending the boundaries of both expression system technology and process development and manufacturing.

  2. Novel amplification technology to challenge PCR in diagnostics 8/21/2000
    With PCR sitting pretty as king of the hill in nucleic acid amplification, who needs a competing technology?...
  3. Understanding Cryopreservation Of Cellular Therapies 2/13/2020

    Cryopreservation is the process of using ultra-low temperatures to preserve living cells and tissues for a prolonged time period.

  4. The US Drug Pricing System Needs to Be Fixed 6/16/2021

    Reforms to the U.S. drug pricing environment are required, but to improve patients’ health outcomes, reforms must be grounded in a comprehensive understanding of the current drug pricing system. Otherwise, policymakers will make things worse, not better.

  5. Advancements In Small Volumes Drug Freezing Techniques 12/5/2023

    Explore the benefits of different freezing techniques for small batches and their ability to meet the specific requirements and characteristics of different drug substances.

  6. How Ring's Single-Capsid Protein Approach Optimizes Viral Delivery 11/5/2024

    Complexity and manufacturability have an inverse relationship. Ring’s platform seeks to simplify highly complex gene therapy production by making the most of biology.

  7. How Data Analytics Accelerates Transition To Bioprocessing 4.0 4/7/2023

    Following successful Industry 4.0 implementation in the automotive, communications, aerospace, and other industries, the biopharma industry is now joining the digital revolution.

  8. Seven Softgel Myths: Are You Missing Your Softgel Opportunity?

    Softgels are a popular dose format among consumers, thanks to their high swallowability and quick onset of action, yet pharmaceutical developers may not even consider them. Why the disconnect?

  9. Save Time And Money On Turn-Over Packages, Pre-Validation, And Factory Acceptance Testing 1/14/2013

    Documentation developed, information collected, and labor expended to create a turn-over package (TOP) for a biopharm modular system represents a significant cost to any project. So much so, that when working with a client, we jokingly say “we sell documentation and you get the system for free.”  To properly validate a system, you have to make the investment in documentation, but you can realize significant labor and cost advantages when developing TOP documentation and pre-validating your modular system via Factory Acceptance Testing in a closed-shop environment. By Mark McGlynn, President, IPEC

  10. Cell & Gene Therapies: How Can Our Knowledge Of 2023 Inform Our Predictions For 2024? 1/8/2024

    2024 promises a potential turnaround and blue skies for cell and gene therapies. Let’s explore each modality’s prospects: oligos and mRNA, cell therapies, and viral gene therapies.